These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Moschonas IC; Goudevenos JA; Tselepis AD Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282 [TBL] [Abstract][Full Text] [Related]
3. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. Moon JY; Franchi F; Rollini F; Angiolillo DJ J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918 [TBL] [Abstract][Full Text] [Related]
4. Vorapaxar for the reduction of atherothrombotic events. Diaz-Ricart M; Escolar G Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871 [TBL] [Abstract][Full Text] [Related]
7. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022 [TBL] [Abstract][Full Text] [Related]
8. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
9. Vascular PAR-1: activity and antagonism. Lang NN; Guðmundsdóttir IJ; Newby DE Cardiovasc Ther; 2011 Dec; 29(6):349-61. PubMed ID: 20528879 [TBL] [Abstract][Full Text] [Related]
10. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis. Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E; Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854 [TBL] [Abstract][Full Text] [Related]
14. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. French SL; Arthur JF; Tran HA; Hamilton JR Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961 [TBL] [Abstract][Full Text] [Related]
15. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390 [TBL] [Abstract][Full Text] [Related]
16. Vorapaxar in the secondary prevention of atherothrombotic events. Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA; N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427 [TBL] [Abstract][Full Text] [Related]
17. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075 [TBL] [Abstract][Full Text] [Related]